Skip To Content

Study ID: Merck MK-3475-629

Title:

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Description:
You are participating in the Merck MK-3475-629-00 study.The purpose of this study is to: • test the safety of the research study drug, MK-3475, pembrolizumab/KEYTRUDA®, and to see how well your body handles it. • to see what effect the study drug has on your disease. The use of pembrolizumab in this study is experimental.
Location:
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Disease:
Skin
Stage:
Phase II
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.